Advocacy News Briefs
FORCE advocates for families facing hereditary cancer in areas such as access to care, research funding, insurance and privacy.

Stay up to date on research and information

Sign Up for FORCE Newsletters

Privacy, Policy and Legal Issues > News Brief Archive

News Brief Archive

2024

9/9/2024 - Signed on to a comment letter encouraging coverage of computed tomography colonography (CTC) procedures and follow-up colonoscopies in the proposed Medicare and Medicaid Program 2025 Physician Fee Schedule (PFS) rule.

8/2/2024 - Responded to an RFI from Representatives DeGette and Bucshon, providing input on the successes, gaps and unmet needs in the 21st Century Cures and CURES 2.0 initiatives, suggesting components for future efforts.

7/16/2024 - Supported a statement expressing concern about the Supreme Court’s decision to eliminate the Chevron doctrine deference precedent and the impact the decision may have on those affected by colorectal and other cancers.

7/2/2024 - Joined more than 50 organizations in submitting feedback on the draft guidance for the second cycle of the Medicare Drug Price Negotiation Program, which will impact drug pricing as well as innovation.

5/14/2024 - Urged the House and Senate Appropriations Committees to create a Colorectal Cancer Research Program within the Department of Defense Congressionally Directed Medical Research Programs.

4/29/2024 - Sent the Administrator of the Centers for Medicare & Medicaid Services (CMS) feedback and recommendations on its Medicare Advantage and Prescription Drug Programs: Part C and Part D Medicare Prescription Payment Plan Model Documents.

4/3/2024 - Submitted comments to Senator Cassidy and the HELP Committee in response to an RFI regarding oversight of clinical diagnostic tests, known as in vitro diagnostics (IVDs) and laboratory-developed tests (LDTs).

3/15/2024 - Joined the Coalition to Increase Access to Cancer Care (CIACC) in comments to House leadership on efforts to strengthen the Employee Retirement Income Security Act (ERISA) and emphasize the need to pass the Cancer Drug Parity Act.

3/1/2024 - Provided feedback to CMS on the Medicare Advantage Advanced Notice and accompanying Part D Redesign Program provisions aimed at reducing and managing beneficiary out-of-pocket costs in the Medicare Part D program.

2/29/2024 - Wrote sponsors to endorse the BENEFIT Act, which would require the FDA to include in the benefit-risk assessment framework of a new drug application how patient experience data was considered in the review process.

2/28/2024 - Encouraged congressional leadership to support and enact the Equitable Community Access to Pharmacist Services Act to ensure that Medicare beneficiaries maintain access to essential pharmacist services.

2/22/2024 - Joined over 200 orgs in urging Congress to make important telehealth flexibilities permanent, to provide certainty, and safeguard against this important policy getting left behind among competing priorities at the end of the year.

1/28/2024 - Sent comments to the FL Senate Banking and Insurance Committee in support of SB 932, legislation aiming to expand coverage of high-risk, supplemental breast screenings and diagnostic imaging with no patient cost-sharing.

1/16/2024 - Joined stakeholders in a letter to President Biden asking that he recognize March as National Colorectal Cancer Awareness Month and light the White House blue to honor those we have lost and those fighting this disease.

 

Sponsored By:

Genentech A Member of the Roche Group Merck